FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to immunogenic compositions of gastrin-17, and can be used in medicine to treat diseases associated with the pathology of gastrin secretion. Immunogenic composition includes a) a first component containing an adjuvant which contains an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix, and b) a second component containing at least one gastrin-17 peptide immunogen linked to a second peptidic alpha-helix. Said first peptidic alpha-helix of the first part is coiled with the second peptidic alpha-helix of the second part, thereby forming a coiled spiral structure.
EFFECT: invention makes it possible to increase the effectiveness of immunisation against gastrin-17, overcoming the natural immunological tolerance against the autologous antigen G17M.
15 cl, 3 dwg, 2 tbl, 7 ex
Authors
Dates
2018-08-15—Published
2014-05-16—Filed